ResearchWorks Archive

Prevalent expression of the immunostimulatory MHC class I chain–related molecule is counteracted by shedding in prostate cancer

Show simple item record

dc.contributor.author Wu, Jennifer D. en_US
dc.contributor.author Higgins, Lily M. en_US
dc.contributor.author Steinle, Alexander en_US
dc.contributor.author Cosman, David en_US
dc.contributor.author Haugk, Kathy en_US
dc.contributor.author Plymate, Stephen R. en_US
dc.date.accessioned 2010-05-06T20:10:17Z
dc.date.available 2010-05-06T20:10:17Z
dc.date.issued 2004-08-16 en_US
dc.identifier.citation Wu JD, Higgins LM, Steinle A, et al. Prevalent expression of the immunostimulatory MHC class I chain–related molecule is counteracted by shedding in prostate cancer. J Clin Invest. 2004;114(4):560-568. en_US
dc.identifier.other 10.1172/JCI22206 en_US
dc.identifier.uri http://www.jci.org/articles/view/22206 en_US
dc.identifier.uri http://hdl.handle.net/1773/15883
dc.description.abstract The MHC class I chain–related molecules (MICs) have previously been shown to be induced on most epithelial tumor cells. Engagement of MIC by the activating immune receptor NKG2D triggers NK cells and augments antigen-specific CTL anti-tumor immunity. The MIC-NKG2D system was proposed to participate in epithelial tumor immune surveillance. Paradoxically, studies suggest that tumors may evade MIC-NKG2D–mediated immunity by MIC shedding–induced impairment of effector cell function. Here we demonstrate the first evidence to our knowledge of a significant correlation of MIC shedding and deficiency in NK cell function with the grade of disease in prostate cancer. MIC is widely expressed in prostate carcinoma. The presence of surface target MIC, however, is counteracted by shedding. A significant increase in serum levels of soluble MIC (sMIC) and deficiency in NK cell function was shown in patients with advanced cancer. Finally, the deficiency in NK cell function can be overcome by treatment with IL-2 or IL-15 in vitro. Our results suggest that (a) deficiency in MIC-NKG2D immune surveillance may contribute to prostate cancer progression, (b) sMIC may be a novel biomarker for prostate cancer, and (c) using cytokines to restore MIC-NKG2D–mediated immunity may have clinical significance for prostate cancer in cell-based adaptive immunotherapy. en_US
dc.description.sponsorship NIH grants RO1DK52683 and PO1 CA85859 and a Department of Veterans Affairs Research Service Award to S.R. Plymate and Department of Defense New Investigator’s Award W81XWH-04-1-0577 to J.D. Wu. en_US
dc.language.iso en_US en_US
dc.title Prevalent expression of the immunostimulatory MHC class I chain–related molecule is counteracted by shedding in prostate cancer en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search ResearchWorks


Advanced Search

Browse

My Account

Statistics